Dare Bioscience Q3 EPS $(0.09) Beats $(0.10) Estimate, Sales $1.00M Beat $430.00K Estimate, Cash Balance $13.9M
Portfolio Pulse from Benzinga Newsdesk
Dare Bioscience reported Q3 losses of $(0.09) per share, beating the analyst consensus estimate of $(0.10) by 9 percent. This is a 13.75 percent decrease over losses from the same period last year. The company also reported quarterly sales of $1.00 million, beating the analyst consensus estimate of $430.00 thousand by 132.56 percent. The company's cash balance stands at $13.9M.
November 09, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dare Bioscience reported better than expected Q3 results with EPS and sales beating estimates. However, the company's losses increased compared to the same period last year.
Dare Bioscience's Q3 results were better than expected, with both EPS and sales beating estimates. This could potentially lead to a positive reaction in the stock price. However, the increase in losses compared to the same period last year might temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100